Impact of muscle loss on chemotherapy side effects in cancer patients
Official title: Effect of Sarcopenia on the Occurrence of Toxicity Related to Anti-cancer Treatments. Prospective Cohort Study
Run by Centre Hospitalier Metropole Savoie · NCT06274268 · Data updated 2026-11-12
This study is testing how muscle loss affects the side effects of chemotherapy in cancer patients to see if it makes treatment harder to handle.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 700 (estimated) |
| Sponsor | Centre Hospitalier Metropole Savoie Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Chambéry) |
| Status | Recruiting |
| Started | June 24, 2024 |
| Main results expected | May 1, 2027 |
| Study ends | May 1, 2028 |
| Registry record updated | October 8, 2026 |
| Trial ID | NCT06274268 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include adults over 18 with a histologically confirmed solid malignant tumor requiring systemic treatment.
✕Probably not a fit
Patients with cancers not requiring systemic treatment or those with a history of cancer in the past five years may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This clinical trial aims to investigate how sarcopenia, or muscle loss, affects the occurrence of treatment-related toxicity during the initial phase of chemotherapy in cancer patients. The study will assess participants' body composition and muscular performance through various tests, including impedancemetry and physical performance evaluations. Data will be collected at multiple points: during the first chemotherapy session, after the second course, and at 6 and 12 months post-treatment. An exploratory component will also focus on patients undergoing specific breast cancer treatments.
Why it matters
Potential benefit: If successful, this study could help identify patients at higher risk for chemotherapy-related toxicity, allowing for tailored treatment approaches.
How similar studies have gone: While the specific approach of this study may be novel, similar studies have indicated that sarcopenia can influence treatment outcomes in cancer patients.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients over 18 years old * Patient with a diagnosis of a histologically proven solid malignant tumor with an indication for systemic treatment during initial treatment. * CT/PET performed within 45 days before initiation of systemic treatment. * Patient able to sign informed consent for participation in the study * Patient affiliated to a social security system Exclusion Criteria: * History of cancer in the five years preceding inclusion other than localized skin or cervical cancers. * Patient with cancer not requiring systemic treatment. * Pregnant women. * Patient with a pace maker or defibrillator * Patient deprived of liberty or benefiting from a legal protection measure
Where it's running
-
Centre Hospitalier Metropole Savoie
Chambéry, France Recruiting
Study contacts
- Principal investigator: Aurelie FILLON — Centre Hospitalier Metropole Savoie
- Study coordinator: Aurelie FILLON
- Email: aurelie.fillon@ch-metropole-savoie.fr
- Phone: 04.79.96.58.13
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Sarcopenia in Patients After Cardiac Surgery
This observational study tests how common sarcopenia is after cardiac surgery and whether current care helps improve muscle mass and function.
-
Bone marrow mesenchymal stem cell injection for sarcopenia
This study tests whether CG-BM1, a stem cell injection, can be safely given to adults with sarcopenia to see if it helps improve muscle health.
-
GLP-1 receptor agonist use and muscle health in adults with obesity without diabetes
This study tests whether GLP-1 receptor agonists affect muscle mass and strength in adults with obesity who don’t have diabetes.
-
Sarcopenia and Epidural Steroid Injections in Lumbar Spinal Stenosis
We’re testing how sarcopenia relates to pain, function, and quality of life after a routine interlaminar epidural steroid injection in people with lumbar spinal stenosis.
-
Heat therapy during reduced activity to protect heart and muscle health
A randomized trial tests whether daily Finnish dry sauna help preserves cardiovascular and muscle health when daily activity is reduced for seven days in healthy adults.
-
Using Multimodal Ultrasound to Check Muscle Mass in Metabolic Disease Patients
This study tests whether a multimodal ultrasound approach can accurately measure muscle mass in people with metabolic syndrome, obesity, sarcopenia, or type 2 diabetes.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.